All articles by Milena Izmirlieva

Precise magnitude of hospital markups revealed in the US

A study by Xiao and colleagues was published in JAMA Internal Medicine on 18 April and sheds light on the…
Delta variant prompts change in policy responses

The B.1.617.2 variant of the COVID-19 virus, first identified in India in December 2020 and designated as the Delta variant…
Reimbursement outcomes for combination therapies in breast cancer

Combination therapies are particularly common in breast cancer. Data from our PharmOnline International (POLI) database indicate that combination therapies account for 70.3%…
Vaccine hesitancy boosts risks from vaccine nationalism

There has been a lot of talk about vaccine nationalism - the practice of countries hoarding limited vaccine supplies - and the…
Trump resurrects International Reference Pricing (IRP) proposal on pharmaceuticals with executive order

The global pharmaceutical industry is bracing itself for the "granddaddy" of all pharma pricing proposals following a series of executive…

COVID-19 pandemic: Health system surge capacity

COVID-19, a novel coronavirus, which emerged in China in December 2019 and has since spread around the world, will test…
Risks to UK pharmaceutical spending from a US-UK free trade deal

A leaked document about UK-US free trade deal discussions back in 2017 has dominated UK media coverage over the past…
Challenges with risk sharing in Eastern Europe raised at ISPOR Europe meeting

While attending the ISPOR Europe 2019 meeting in Copenhagen, I came across an interesting discussion of the unique challenges that…
United States experience dramatic shift in public share of healthcare spending

Public spending on healthcare has risen dramatically in the United States from just under 50% of total healthcare spending in…
Our pricing and reimbursement research presented at ISPOR Europe

In research, presented at the ISPOR Europe meeting in Barcelona on 13 October, Associate Director Milena Izmirlieva examines the impact…